BBK Holdings opens European subsidiary to support clinical trials

By Maggie Lynch

- Last updated on GMT

(Image: Getty/Oleski Liskonih)
(Image: Getty/Oleski Liskonih)

Related tags Clinical trials Clinical data Patient centricity Clinical trial Patient recruitment GDPR Brexit

BBK Holdings, parent company of BBK Worldwide, has established BBK Patient Experience Limited to support patient data protection in clinical trials and add to its footprint in the EU.

BBK Holdings parent company of BBK Worldwide announced the building of additional subsidiary in the EU BBK Patient Experience Limited located in Dublin, Ireland to support the company’s reimbursement programs to increase access to care while supporting data protection initiatives.

Joan Bachenheimer, founding principal and CEO of BBK Worldwide told us that establishing this subsidiary in the EU served a twofold purpose. It will facilitate requirements for international banking organizations, and support data protection mandated by the European Union’s General Data Protection Regulation (GDPR​).

“This was the most logical move in order to not only be able to respond quickly to the shifting global landscape but to ensure we provide patients with the services they need for a positive clinical trial experience,”​ Bachenheimer added.

GDPR applies not only to EU organizations but also located outside of Europe that provides goods or services to citizens in the region.

BBK’s technology-based reimbursement and travel programs, RSG Card and RSG Arrive, were launched in 2013. Bachenheimer told us that reimbursement​ is important in clinical trials as it removes barriers to patient participation and removes administrative tasks from the site. The company released a report stated that 40% of patients said travel assistance would have been helpful in the clinical trial experience.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers